- Home
- MERC vs GOSS Comparison
MERC vs GOSS Comparison
Compare MERC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- GOSS
- Stock Information
- Founded
- MERC 1968
- GOSS 2015
- Country
- MERC Canada
- GOSS United States
- Employees
- MERC N/A
- GOSS N/A
- Industry
- MERC Paper
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- MERC Basic Materials
- GOSS Health Care
- Exchange
- MERC Nasdaq
- GOSS Nasdaq
- Market Cap
- MERC 271.5M
- GOSS 262.5M
- IPO Year
- MERC 1987
- GOSS 2019
- Fundamental
- Price
- MERC $3.89
- GOSS $1.38
- Analyst Decision
- MERC Hold
- GOSS Strong Buy
- Analyst Count
- MERC 3
- GOSS 3
- Target Price
- MERC $5.33
- GOSS $7.33
- AVG Volume (30 Days)
- MERC 434.8K
- GOSS 2.5M
- Earning Date
- MERC 07-31-2025
- GOSS 08-11-2025
- Dividend Yield
- MERC 7.75%
- GOSS N/A
- EPS Growth
- MERC N/A
- GOSS N/A
- EPS
- MERC N/A
- GOSS N/A
- Revenue
- MERC $1,996,904,000.00
- GOSS $124,590,000.00
- Revenue This Year
- MERC $2.43
- GOSS N/A
- Revenue Next Year
- MERC $6.12
- GOSS $91.14
- P/E Ratio
- MERC N/A
- GOSS N/A
- Revenue Growth
- MERC N/A
- GOSS N/A
- 52 Week Low
- MERC $3.20
- GOSS $0.66
- 52 Week High
- MERC $8.57
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- MERC 58.53
- GOSS 61.04
- Support Level
- MERC $3.52
- GOSS $1.20
- Resistance Level
- MERC $4.04
- GOSS $1.39
- Average True Range (ATR)
- MERC 0.16
- GOSS 0.09
- MACD
- MERC 0.06
- GOSS 0.00
- Stochastic Oscillator
- MERC 76.92
- GOSS 82.91
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.